deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04382053

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia

Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function

Sponsor: Novartis Pharmaceuticals

Conditions COVID-19 Pneumonia, Impaired Respiratory Function
Interventions DFV890 Standard of Care (SoC)
Updated 17 times since 2020 Last updated: Jun 27, 2022 Started: May 27, 2020 Primary completion: Dec 10, 2020 Completion: Dec 24, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19 Pneumonia, Impaired Respiratory Function, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 17 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2022 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Dec 2021 — Jun 2022 [monthly]

    Completed PHASE2

  2. Jun 2021 — Dec 2021 [monthly]

    Completed PHASE2

  3. Apr 2021 — Jun 2021 [monthly]

    Completed PHASE2

  4. Feb 2021 — Apr 2021 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  6. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  8. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  11. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  12. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Barnaul, Russia , Budapest, Hungary , Buenos Aires, Argentina , CABA, Argentina , Chelyabinsk, Russia , Coimbatore, India , George, South Africa , Hanover, Germany , Harderwijk, Netherlands and 17 more locations